UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 14,003 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 5.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 251,256 shares of the medical research company's stock after selling 14,003 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.49% of Charles River Laboratories International worth $49,490,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Financial Counselors Inc. grew its position in Charles River Laboratories International by 22.6% in the third quarter. Financial Counselors Inc. now owns 26,592 shares of the medical research company's stock valued at $5,238,000 after purchasing an additional 4,896 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Charles River Laboratories International by 4.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,812 shares of the medical research company's stock valued at $1,933,000 after buying an additional 423 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Charles River Laboratories International in the third quarter valued at $2,915,000. Blueshift Asset Management LLC acquired a new position in Charles River Laboratories International during the third quarter worth $446,000. Finally, Glenmede Trust Co. NA raised its position in Charles River Laboratories International by 9.5% during the third quarter. Glenmede Trust Co. NA now owns 1,210 shares of the medical research company's stock worth $238,000 after acquiring an additional 105 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Performance

NYSE CRL traded down $0.03 during trading on Wednesday, reaching $199.27. The company's stock had a trading volume of 278,822 shares, compared to its average volume of 618,805. The firm has a 50 day moving average price of $194.24 and a 200 day moving average price of $204.24. Charles River Laboratories International, Inc. has a 12 month low of $176.48 and a 12 month high of $275.00. The firm has a market capitalization of $10.19 billion, a price-to-earnings ratio of 24.93, a price-to-earnings-growth ratio of 5.19 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.72 earnings per share. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Charles River Laboratories International announced that its board has authorized a stock repurchase plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 9.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on CRL shares. The Goldman Sachs Group lowered their price objective on shares of Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating on the stock in a research note on Thursday, August 8th. Evercore ISI upped their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research note on Thursday, November 7th. Redburn Atlantic initiated coverage on Charles River Laboratories International in a research report on Monday, October 14th. They issued a "sell" rating and a $151.00 price objective for the company. Bank of America lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $250.00 to $215.00 in a report on Wednesday, October 2nd. Finally, Citigroup cut shares of Charles River Laboratories International from a "neutral" rating to a "sell" rating and reduced their price objective for the stock from $215.00 to $175.00 in a research report on Tuesday, October 1st. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $214.38.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).